Inovio estimates $36.7M cash at June 30

Inovio Pharmaceuticals, Inc. provides a preliminary estimate of its liquidity, stating that as of June 30, 2026 it had approximately $36.7 million in cash and cash equivalents.

Rhea-AI Filing Summary

Inovio Pharmaceuticals, Inc. provides a preliminary estimate of its liquidity, stating that as of June 30, 2026 it had approximately $36.7 million in cash and cash equivalents. This figure is based on management estimates and has not yet gone through full quarter-end closing procedures.

The estimate is described as preliminary unaudited information and may change once financial closing activities and reviews of internal controls are completed. The company notes that its independent registered public accounting firm, Ernst & Young LLP, has not audited, reviewed, examined, or compiled this data, and gives cautionary language about forward-looking statements and potential differences from final results.

Filing Explained

The filing’s preliminary June 30 cash estimate of $36.7 million is above the $26,271,650 reported at March 31, when short-term investments of $11,409,607 sat alongside it; this does not establish June 30 cash coverage.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Key Figures

Preliminary cash and cash equivalents: $36.7 million

1 metrics

Preliminary cash and cash equivalents $36.7 million Estimated as of June 30, 2026, based on preliminary unaudited information

Key Terms

preliminary unaudited information, forward-looking statements, Private Securities Litigation Reform Act of 1995, internal controls over financial reporting

4 terms

preliminary unaudited information financial

"The cash and cash equivalents information above is based on preliminary unaudited information"

forward-looking statements regulatory

"This ... contains forward-looking statements within the meaning of the Private Securities Litigation"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Private Securities Litigation Reform Act of 1995 regulatory

"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

internal controls over financial reporting financial

"as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting"

Internal controls over financial reporting are the policies, procedures and checks a company uses to make sure its accounting and financial statements are accurate, complete and free from significant error or fraud. They matter to investors because strong controls lower the risk of misleading results or surprise restatements—think of them as a quality checkpoint on a factory line that helps prevent costly defects that could damage a company’s value and reputation.

Earnings Snapshot

Preliminary cash and cash equivalents: $36.7 million

Quarter ended June 30, 2026

Preliminary cash and cash equivalents $36.7 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cash balance did Inovio Pharmaceuticals (INO) estimate as of June 30, 2026?

Inovio Pharmaceuticals estimates holding approximately $36.7 million in cash and cash equivalents as of June 30, 2026. This is a preliminary, unaudited figure based on management’s estimates for the quarter ended June 30, 2026.

Is Inovio’s (INO) estimated $36.7 million cash balance audited?

No. The $36.7 million cash and cash equivalents estimate is described as preliminary unaudited information. Ernst & Young LLP has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to this data and provides no assurance on it.

What period does the new INO financial information relate to?

The estimate relates to Inovio’s cash and cash equivalents position as of June 30, 2026, tied to the quarter ended June 30, 2026. It covers only this liquidity metric and is not a full set of quarterly financial results.

Why might Inovio’s (INO) actual results differ from this preliminary cash estimate?

The company notes actual results for the quarter ended June 30, 2026 could differ materially from the estimate due to changes in assumptions, updates to management estimates, and completion of internal controls reviews and other quarter-end and year-end procedures.

How does Inovio (INO) characterize the forward-looking nature of this cash estimate?

Inovio characterizes the estimate and related discussion as forward-looking statements under the Private Securities Litigation Reform Act of 1995, stressing that they are based on current expectations and are subject to risks and uncertainties that could cause material differences.

Does Inovio’s (INO) preliminary cash information automatically carry over into other SEC disclosures?

No. The company states this information is being furnished and not deemed “filed” for certain liability purposes, and it is not incorporated into other Securities Act disclosures unless specifically referenced in those separate documents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:04 PM Accepted by SEC EDGAR 07/29/2026 - 04:03 PM Learn about SEC filing dates

false 0001055726 0001055726 2026-07-29 2026-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2026

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-14888		33-0969592
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

660 W. Germantown Pike Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		INO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Inovio Pharmaceuticals, Inc. (the “Company”) is providing the following financial information. As of June 30, 2026, the Company estimates that its cash and cash equivalents were approximately $36.7 million.

The cash and cash equivalents information above is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2026, is not a comprehensive statement of our financial results as of and for the quarter ended June 30, 2026, and is subject to completion of the Company’s financial closing procedures.

The preliminary financial data included in this current report has been prepared by, and is the responsibility of, the Company’s management. Ernst & Young LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto.

The information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the preliminary estimate of the Company’s cash and cash equivalents as of June 30, 2026. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including, without limitation, our actual results for the quarter ended June 30, 2026 may differ materially from our preliminary estimates as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting or other quarter-end and year-end procedures. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s business are described in detail in its SEC filings, including, in the section of the prospectus supplement titled “Risk Factors,” filed with the SEC on July 29, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				INOVIO PHARMACEUTICALS, INC.
Date: July 29, 2026				By:		/s/ Peter Kies
						Peter Kies
						Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.5 KB